|
covid-19 |
76 |
|
sars-cov-2 |
74 |
|
coronavirus |
48 |
|
antiviral |
33 |
|
interferon |
30 |
|
sars-cov |
29 |
|
adult |
28 |
|
flavivirus |
25 |
|
lipidomics |
25 |
|
treatment |
25 |
|
zika |
24 |
|
pathogenesis |
23 |
|
viral load |
21 |
|
animal |
20 |
|
enterovirus |
20 |
|
mouse |
20 |
|
influenza |
19 |
|
susceptibility |
19 |
|
viral replication |
19 |
|
aged |
18 |
|
humans |
18 |
|
mers-cov |
18 |
|
age |
17 |
|
inhibitor |
17 |
|
metabolomics |
17 |
|
temperature |
17 |
|
vaccine |
17 |
|
diagnosis |
16 |
|
fatty acid |
16 |
|
influenza virus |
16 |
|
omicron |
16 |
|
pandemic |
16 |
|
transmission |
16 |
|
uplc-esi-q-tof-ms |
16 |
|
child |
15 |
|
female |
15 |
|
hemagglutinin |
15 |
|
influenza, human - epidemiology - virology |
15 |
|
male |
15 |
|
middle aged |
15 |
|
animals |
14 |
|
china |
14 |
|
immune activation |
14 |
|
intestine |
14 |
|
protease |
14 |
|
replication |
14 |
|
ace2 |
13 |
|
adolescent |
13 |
|
bunyavirales |
13 |
|
cell line |
13 |
|
cytokine and chemokine response |
13 |
|
h5n1 |
13 |
|
hong kong - epidemiology |
13 |
|
rhizopus microsporus |
13 |
|
rnai |
13 |
|
sace2 |
13 |
|
species index: fungi |
13 |
|
acute hepatitis |
12 |
|
animal tissue |
12 |
|
biomarkers |
12 |
|
bronchiectasis |
12 |
|
case report |
12 |
|
chronic obstructive lung disease |
12 |
|
controlled study |
12 |
|
disease outbreaks |
12 |
|
infectivity |
12 |
|
influenza a virus, h1n1 subtype - genetics |
12 |
|
sftsv |
12 |
|
2′-o-methyltransferase |
11 |
|
aged, 80 and over |
11 |
|
animal cell |
11 |
|
anthranilic acid |
11 |
|
ba.5.2 |
11 |
|
bat |
11 |
|
broad spectrum |
11 |
|
coronavirus disease 2019 |
11 |
|
endoplasmic reticulum |
11 |
|
entry |
11 |
|
feces analysis |
11 |
|
hamster |
11 |
|
human immunodeficiency virus |
11 |
|
influenza a virus |
11 |
|
live attenuated vaccine |
11 |
|
mucosal immunity |
11 |
|
murine |
11 |
|
n501y |
11 |
|
neutralizing antibodies |
11 |
|
nsp16 |
11 |
|
rat |
11 |
|
sars |
11 |
|
sars-cov-2 variants |
11 |
|
sterilizing immunity |
11 |
|
t-cell response |
11 |
|
adaptation |
10 |
|
airborne infection |
10 |
|
animal experiment |
10 |
|
animal model |
10 |
|
antibody titer |
10 |
|
antigen-presentation |
10 |
|
birds - virology |
10 |
|
burkholderia pseudomallei |
10 |
|
cell line, tumor |
10 |
|
cell tropism |
10 |
|
chick embryo |
10 |
|
child, preschool |
10 |
|
coronavirus - immunology - pathogenicity - physiology |
10 |
|
coronavirus infections - immunology - virology |
10 |
|
cytokines - biosynthesis - immunology |
10 |
|
cytokines - blood |
10 |
|
d222g |
10 |
|
d225g |
10 |
|
damplicon |
10 |
|
diagnostics |
10 |
|
dogs |
10 |
|
h1n1 |
10 |
|
hemagglutinin glycoproteins, influenza virus - genetics - metabolism |
10 |
|
hong kong |
10 |
|
human neutralizing antibody |
10 |
|
infant |
10 |
|
influenza a virus, h1n1 subtype - genetics - pathogenicity |
10 |
|
influenza a virus, h1n1 subtype - isolation and purification |
10 |
|
influenza a virus, h1n1 subtype - physiology |
10 |
|
influenza a virus, h5n1 subtype - physiology |
10 |
|
influenza h1n1 |
10 |
|
influenza in birds - virology |
10 |
|
influenza, human - immunology - pathology - virology |
10 |
|
influenza, human - virology |
10 |
|
linker-immunodominant site |
10 |
|
lung injury |
10 |
|
melioidosis |
10 |
|
mers |
10 |
|
middle east |
10 |
|
mutation - genetics |
10 |
|
nasal turbinate |
10 |
|
phage display |
10 |
|
plasma |
10 |
|
pneumonia, viral - immunology - virology |
10 |
|
receptor binding domain |
10 |
|
seroprevalence |
10 |
|
sialic acid |
10 |
|
spike protein |
10 |
|
swine - virology |
10 |
|
swine diseases - virology |
10 |
|
swine-origin |
10 |
|
upper respiratory tract |
10 |
|
virus |
10 |
|
virus replication |
10 |
|
virus replication - physiology |
10 |
|
young adult |
10 |
|
aged mice |
9 |
|
airway organoid |
9 |
|
anti-bacterial agents - pharmacology |
9 |
|
antibodies, viral - blood |
9 |
|
bagg albino mouse |
9 |
|
bioaerosols |
9 |
|
cancer |
9 |
|
cell surface |
9 |
|
circrna |
9 |
|
clinical outcome |
9 |
|
cohort studies |
9 |
|
coronavac |
9 |
|
emerging |
9 |
|
epidemiology |
9 |
|
ex vivo |
9 |
|
fc-rbd |
9 |
|
genome |
9 |
|
h7n9 |
9 |
|
human primary nasal epithelial cells |
9 |
|
immune protection |
9 |
|
inactivated vaccine |
9 |
|
internalization |
9 |
|
middle east respiratory syndrome |
9 |
|
model |
9 |
|
mrna |
9 |
|
mycobacterium tuberculosis |
9 |
|
neutralizing antibody |
9 |
|
novel |
9 |
|
nucleolin |
9 |
|
omicron variant |
9 |
|
operating rooms |
9 |
|
orchitis |
9 |
|
phosphatidic acid phosphatases |
9 |
|
pneumonia |
9 |
|
post-ba.2/5 subvariants |
9 |
|
proximal differentiation |
9 |
|
reverse genetics |
9 |
|
sars-cov-2 variants of concern |
9 |
|
severity of illness index |
9 |
|
specific |
9 |
|
steroid |
9 |
|
testis |
9 |
|
vopba |
9 |
|
weanling mice |
9 |
|
xbb.1 |
9 |
|
zika virus |
9 |
|
zoonosis |
9 |
|
25-hydroxycholesterol |
8 |
|
3clpro inhibitor |
8 |
|
a(h3n2) |
8 |
|
age factors |
8 |
|
allosteric-site inhibitor |
8 |
|
am580 |
8 |
|
animal models |
8 |
|
antibodies, neutralizing - blood |
8 |
|
antibody |
8 |
|
antibody blood level |
8 |
|
antibody formation |
8 |
|
antibody response |
8 |
|
apoptosis |
8 |
|
asymptomatic |
8 |
|
asymptomatic infection |
8 |
|
avian influenza virus |
8 |
|
betacoronavirus |
8 |
|
broad-spectrum antiviral treatment |
8 |
|
case study |
8 |
|
caspase |
8 |
|
chemical genetics |
8 |
|
chemicals and cas registry numbers |
8 |
|
chemokine |
8 |
|
chicken |
8 |
|
china - epidemiology |
8 |
|
clarithromycin |
8 |
|
conjunctiva |
8 |
|
covid‐19 |
8 |
|
cross-reactive |
8 |
|
cytokine |
8 |
|
detection |
8 |
|
diagnostic |
8 |
|
dipeptidyl peptidase 4 |
8 |
|
disease outbreaks - statistics & numerical data |
8 |
|
emc |
8 |
|
feces - virology |
8 |
|
hcov-emc |
8 |
|
hemagglutination inhibition tests |
8 |
|
high throughput screening |
8 |
|
hku1 |
8 |
|
hospitalized |
8 |
|
human |
8 |
|
hypsugo bat |
8 |
|
il-8 |
8 |
|
incidence |
8 |
|
influenza a virus, h1n1 subtype - genetics - immunology - isolation and purification |
8 |
|
influenza a virus, h1n1 subtype - genetics - isolation & purification - physiology |
8 |
|
influenza a virus, h1n1 subtype - immunology |
8 |
|
influenza a virus, h1n1 subtype - isolation & purification - pathogenicity |
8 |
|
influenza vaccines - immunology |
8 |
|
influenza, human - epidemiology - pathology - virology |
8 |
|
influenza, human - immunology |
8 |
|
integrative-omics |
8 |
|
interferon lambda 1 |
8 |
|
marmosets |
8 |
|
mask |
8 |
|
metalloimmunity |
8 |
|
metalloproteomics |
8 |
|
middle east respiratory syndrome coronavirus |
8 |
|
nanopore sequencing |
8 |
|
naproxen |
8 |
|
neutralization |
8 |
|
ns5 |
8 |
|
nsp1 |
8 |
|
oc43 |
8 |
|
oseltamivir |
8 |
|
respiratory system - virology |
8 |
|
reverse transcriptase polymerase chain reaction |
8 |
|
rna, viral - genetics |
8 |
|
rt-pcr |
8 |
|
rt‐pcr |
8 |
|
saliva |
8 |
|
sars‐cov‐2 |
8 |
|
screening |
8 |
|
seasons |
8 |
|
serial |
8 |
|
shedding |
8 |
|
spike glycoprotein |
8 |
|
spike mutant |
8 |
|
spike s1/s2 mutant |
8 |
|
spleen |
8 |
|
stool |
8 |
|
t lymphocytes |
8 |
|
tonsil |
8 |
|
urine |
8 |
|
urine - virology |
8 |
|
viral load - physiology |
8 |
|
virus cultivation |
8 |
|
virus shedding |
8 |
|
adenosine synthase a |
7 |
|
amino acid substitution |
7 |
|
antiviral agents - administration and dosage - therapeutic use |
7 |
|
aspergillus |
7 |
|
autoclave |
7 |
|
bacteriological techniques - methods |
7 |
|
bioinorganic chemistry |
7 |
|
bismuth |
7 |
|
bromocriptine |
7 |
|
caco-2 |
7 |
|
cardiac infection |
7 |
|
cardiomyocytes |
7 |
|
cell culture |
7 |
|
clade |
7 |
|
clinic |
7 |
|
coinfection |
7 |
|
combination therapy |
7 |
|
community |
7 |
|
corticosteroid |
7 |
|
culture media - chemistry |
7 |
|
cva16 |
7 |
|
dendritic cells |
7 |
|
dental |
7 |
|
diarrhea - epidemiology - microbiology |
7 |
|
enterovirus d68 |
7 |
|
ev-a71 |
7 |
|
evaluation |
7 |
|
furin cleavage prra motif |
7 |
|
hcov-229e |
7 |
|
heart |
7 |
|
hemagglutinins - genetics |
7 |
|
high infection rate |
7 |
|
human herpesvirus 6b |
7 |
|
immunoglobulin g - blood |
7 |
|
influenza a virus, h1n1 subtype - immunology - pathogenicity |
7 |
|
influenza, human - drug therapy - epidemiology - virology |
7 |
|
interferon antagonist |
7 |
|
intestinal organoids |
7 |
|
ire1 |
7 |
|
klebsiella infections - epidemiology - microbiology |
7 |
|
klebsiella oxytoca - classification - genetics - isolation and purification - pathogenicity |
7 |
|
lightmix e-gene |
7 |
|
macrophages |
7 |
|
mdms |
7 |
|
modcs |
7 |
|
monoinfection |
7 |
|
ms |
7 |
|
mutation |
7 |
|
neurogenesis |
7 |
|
nlrp3 inflammasome |
7 |
|
nsp14 exon and mtase |
7 |
|
nsp3 |
7 |
|
olfactory neuron |
7 |
|
onychomycosis |
7 |
|
orf6 |
7 |
|
oseltamivir - administration and dosage - therapeutic use |
7 |
|
pathogenicity |
7 |
|
plpro |
7 |
|
polymerase chain reaction |
7 |
|
real-time rt-pcr |
7 |
|
recombination |
7 |
|
remdesivir |
7 |
|
respiratory viruses |
7 |
|
route of transmission |
7 |
|
single-tube nested |
7 |
|
spermatogenesis |
7 |
|
stability |
7 |
|
staphylococcus aureus |
7 |
|
sterilization |
7 |
|
t cell responses |
7 |
|
uhplc |
7 |
|
untranslated |
7 |
|
upr |
7 |
|
varicella zoster virus |
7 |
|
viral isolation |
7 |
|
viral variants |
7 |
|
2019 novel coronavirus |
6 |
|
acquired immunodeficiency syndrome - complications - etiology |
6 |
|
adenovirus |
6 |
|
antibody assay |
6 |
|
antigen |
6 |
|
ar-12 |
6 |
|
arbovirus |
6 |
|
artenimol |
6 |
|
aspergillus hongkongensis sp. nov. |
6 |
|
autoantibodies - blood |
6 |
|
bile |
6 |
|
biliary |
6 |
|
biomedicine |
6 |
|
bowel preparation |
6 |
|
brain |
6 |
|
broad-spectrum |
6 |
|
broxyquinoline |
6 |
|
burkholderia infections - etiology - immunology |
6 |
|
carcinoma |
6 |
|
cholangiocarcinoma |
6 |
|
cholangitis |
6 |
|
clr |
6 |
|
common marmoset |
6 |
|
daptomycin |
6 |
|
decolonization |
6 |
|
diagnostic test evaluation |
6 |
|
elderly |
6 |
|
elisa |
6 |
|
eltrombopag |
6 |
|
envelope |
6 |
|
face mask |
6 |
|
flow cytometry |
6 |
|
genome subtraction |
6 |
|
gram-positive bacterial infections - epidemiology - microbiology - mortality - physiopathology |
6 |
|
guanosine |
6 |
|
health care workers |
6 |
|
hedgehog |
6 |
|
hepatitis |
6 |
|
hepatitis e |
6 |
|
hev-c1 |
6 |
|
hexachlorophene |
6 |
|
host-targeted antiviral |
6 |
|
hpyv6 |
6 |
|
hsp90β |
6 |
|
huaiyangshan banyangvirus |
6 |
|
human adenovirus |
6 |
|
imiquimod |
6 |
|
immunogenicity |
6 |
|
interactome |
6 |
|
interferon-gamma - immunology |
6 |
|
internal medicine |
6 |
|
intestinal |
6 |
|
intradermal |
6 |
|
kaletra |
6 |
|
kinase |
6 |
|
lactobacillus rhamnosus gg |
6 |
|
linezolid |
6 |
|
liver disease |
6 |
|
lopinavir |
6 |
|
maldi-tof ms |
6 |
|
malignancy |
6 |
|
medical microbiology |
6 |
|
medical sciences |
6 |
|
merbecovirus |
6 |
|
mers coronavirus |
6 |
|
metabolic fingerprinting |
6 |
|
metabolites |
6 |
|
meticillin-resistant staphylococcus aureus |
6 |
|
microbial sensitivity tests |
6 |
|
microcephaly |
6 |
|
mincle |
6 |
|
molecular modelling |
6 |
|
mortality |
6 |
|
mosquito |
6 |
|
mycophenolate |
6 |
|
mycophenolic acid |
6 |
|
mycoses - etiology - immunology |
6 |
|
nasopharyngeal swab |
6 |
|
newly-weaned hamster |
6 |
|
nosocomial transmission |
6 |
|
novel species |
6 |
|
novobiocin |
6 |
|
nsp2 |
6 |
|
nucleoprotein |
6 |
|
omacetaxine mepesuccinate |
6 |
|
organoids |
6 |
|
outbreak |
6 |
|
pcr |
6 |
|
peptide |
6 |
|
phylogeny |
6 |
|
platform |
6 |
|
point-of-care testing |
6 |
|
polyethylene glycol |
6 |
|
polymerase inhibitor |
6 |
|
polyomavirus |
6 |
|
pooling |
6 |
|
premembrane |
6 |
|
primate |
6 |
|
prognosis |
6 |
|
proinflammatory response |
6 |
|
public health |
6 |
|
rat hepatitis e |
6 |
|
real-time pcr |
6 |
|
realstar® adenovirus pcr kit |
6 |
|
regorafenib |
6 |
|
respiratory |
6 |
|
respiratory virus |
6 |
|
retrospective studies |
6 |
|
rhinovirus |
6 |
|
ribavirin |
6 |
|
risk factors |
6 |
|
rlr |
6 |
|
rodent |
6 |
|
sequencing |
6 |
|
serology |
6 |
|
sfstv |
6 |
|
shewanella - classification - drug effects - isolation & purification - pathogenicity |
6 |
|
spa type |
6 |
|
tetrapeptide |
6 |
|
tick |
6 |
|
tract |
6 |
|
transmissibility |
6 |
|
transmission dynamics |
6 |
|
triclosan |
6 |
|
vancomycin-resistant enterococci |
6 |
|
viral hepatitis |
6 |
|
wuhan |
6 |
|
abbott real time hcv genotype ii |
5 |
|
acly |
5 |
|
actinomycetales - genetics - isolation & purification |
5 |
|
actinomycetales infections - microbiology |
5 |
|
air sampling |
5 |
|
alere i flu a & b |
5 |
|
amniotomy |
5 |
|
anaerobic bacterium |
5 |
|
antibiotic resistance |
5 |
|
antibiotic sensitivity |
5 |
|
antibody affinity |
5 |
|
antifungal susceptibility |
5 |
|
antigens, viral - analysis |
5 |
|
arthritis |
5 |
|
arthritis, infectious - microbiology |
5 |
|
avian influenza |
5 |
|
ba.2.12.1 |
5 |
|
bacterial endocarditis |
5 |
|
bacterial typing techniques |
5 |
|
base sequence |
5 |
|
caliciviridae infections - epidemiology - prevention and control - transmission |
5 |
|
catalase |
5 |
|
clostridium difficile |
5 |
|
clostridium difficile - classification - genetics - isolation and purification |
5 |
|
competing endogenous rna |
5 |
|
contact examination |
5 |
|
cross infection - epidemiology - prevention and control - transmission |
5 |
|
cross infection - microbiology - prevention and control - transmission |
5 |
|
cross infection - prevention and control - transmission - virology |
5 |
|
cytomegalovirus |
5 |
|
delta |
5 |
|
discitis - diagnosis - drug therapy |
5 |
|
disease outbreaks - prevention and control - statistics and numerical data |
5 |
|
disseminated infection recurrence rate |
5 |
|
emerging infectious disease |
5 |
|
enterocolitis, pseudomembranous - epidemiology - microbiology |
5 |
|
epidemic |
5 |
|
ex vivo human lung tissues |
5 |
|
f486v |
5 |
|
famotidine - pharmacology |
5 |
|
genotyping |
5 |
|
glucose homeostasis |
5 |
|
gram-positive bacterial infections - diagnosis - drug therapy |
5 |
|
h1n1 virus |
5 |
|
h9n2 |
5 |
|
handwashing - methods |
5 |
|
hepatitis c |
5 |
|
herpes simplex virus 2 |
5 |
|
herpesviridae |
5 |
|
histamine h2 antagonists - pharmacology |
5 |
|
hnpcs |
5 |
|
human alphaherpesvirus 1 |
5 |
|
ido1 |
5 |
|
implant |
5 |
|
indoleamine 2,3-dioxygenase |
5 |
|
infection |
5 |
|
infection control - methods |
5 |
|
infection control bundle |
5 |
|
influenza a virus, h3n2 subtype - genetics - isolation and purification |
5 |
|
influenza a virus, h7n9 subtype - genetics - isolation and purification |
5 |
|
influenza, human - diagnosis - virology |
5 |
|
influenza, human - prevention and control - transmission - virology |
5 |
|
innate immune response |
5 |
|
kytococcus schroeteri |
5 |
|
lactococcus - classification - genetics - pathogenicity |
5 |
|
library |
5 |
|
luminex nxtag |
5 |
|
medical sciences biology |
5 |
|
metabolic profiling |
5 |
|
methicillin-resistant staphylococcus aureus - isolation and purification |
5 |
|
microbiology |
5 |
|
mirna |
5 |
|
molecular identification |
5 |
|
molecular sequence data |
5 |
|
mucorales |
5 |
|
multiplex real time polymerase chain reaction |
5 |
|
mycobacterium avium complex |
5 |
|
non-aspergillus |
5 |
|
non-dermatophyte |
5 |
|
non-hiv immunosuppression |
5 |
|
norovirus - genetics - isolation and purification |
5 |
|
nosocomial infection |
5 |
|
ns5 protein |
5 |
|
osteomyelitis |
5 |
|
osteomyelitis - microbiology |
5 |
|
patient isolation - methods |
5 |
|
penicillium marneffei |
5 |
|
point-of-care systems |
5 |
|
primary prophylaxis |
5 |
|
prosthesis-related infections - microbiology |
5 |
|
rapid molecular test |
5 |
|
recombinant |
5 |
|
ribotype 027 |
5 |
|
ribotyping |
5 |
|
rna virus |
5 |
|
secondary prophylaxis |
5 |
|
seroepidemiological study |
5 |
|
staphylococcal infections - microbiology - prevention and control - transmission |
5 |
|
stat1 |
5 |
|
stat2 |
5 |
|
tuberculosis |
5 |
|
type ii interferon |
5 |
|
type-ii ifn |
5 |
|
virus evolution |
5 |
|
xpert xpress flu/rsv |
5 |
|
agar gel electrophoresis |
4 |
|
ancylostoma duodenale |
4 |
|
animals, domestic - microbiology |
4 |
|
anisakis simplex |
4 |
|
antibodies |
4 |
|
antiviral agents - pharmacology |
4 |
|
aortic aneurysm, abdominal - complications - diagnosis - pathology - therapy |
4 |
|
ascaris lumbricoides |
4 |
|
autoantibody |
4 |
|
avian |
4 |
|
beta-lactamases - biosynthesis |
4 |
|
blood |
4 |
|
broad-spectrum antiviral drugs |
4 |
|
capnocytophaga - isolation and purification |
4 |
|
carrier state - microbiology |
4 |
|
cephalosporin |
4 |
|
cerebrospinal fluid |
4 |
|
clinical |
4 |
|
cloaca - microbiology |
4 |
|
colonization |
4 |
|
coxiella burnetii |
4 |
|
cryptic species |
4 |
|
cutaneous hyalohyphomycosis |
4 |
|
dna sequencing |
4 |
|
drug repurposing |
4 |
|
drug resistance, multiple, bacterial |
4 |
|
drug resistance, viral |
4 |
|
endocarditis, bacterial - complications - diagnosis - therapy |
4 |
|
engyodontium album |
4 |
|
escherichia coli |
4 |
|
escherichia coli - drug effects - enzymology - isolation & purification |
4 |
|
escherichia coli infections - microbiology |
4 |
|
extended-spectrum beta-lactamase (esbl) |
4 |
|
extended-spectrum β-lactamases |
4 |
|
fungi - isolation and purification |
4 |
|
gallstones - complications - diagnosis - microbiology |
4 |
|
gordonia |
4 |
|
gram-negative bacterial infections - diagnosis - microbiology |
4 |
|
h10n8 |
4 |
|
hepatitis c virus |
4 |
|
histopathology |
4 |
|
hnrnp c |
4 |
|
hongkongensis |
4 |
|
hongkongmyces |
4 |
|
hongkongmyces pedis |
4 |
|
human hepegivirus 1 |
4 |
|
identification |
4 |
|
ifn |
4 |
|
immune breakthrough |
4 |
|
immunodeficiency |
4 |
|
infection control |
4 |
|
influenza a virus - classification - isolation and purification |
4 |
|
influenza a virus, h1n1 subtype - drug effects |
4 |
|
influenza a virus, h7n9 subtype - immunology - isolation and purification |
4 |
|
influenza a virus, h7n9 subtype - isolation and purification |
4 |
|
influenza in birds - epidemiology - virology |
4 |
|
influenza, human - blood - pathology - virology |
4 |
|
influenza, human - epidemiology - immunology - virology |
4 |
|
influenza, human - epidemiology - prevention and control - transmission - virology |
4 |
|
interferon-gamma |
4 |
|
jaundice, obstructive - complications - diagnosis - microbiology |
4 |
|
lactobacillus |
4 |
|
lactobacillus rhamnosus |
4 |
|
lactobacillus rhamnosus - genetics - isolation & purification |
4 |
|
lindgomycetaceae |
4 |
|
liver - radiography |
4 |
|
liver abscess |
4 |
|
liver abscess - complications - diagnosis - microbiology |
4 |
|
maxillary sinusitis - complications - microbiology |
4 |
|
middle east respiratory syndrome coronavirus (mers-cov) |
4 |
|
mirizzi syndrome |
4 |
|
molecular epidemiology |
4 |
|
molecular typing |
4 |
|
multiple myeloma - complications - diagnosis - pathology - therapy |
4 |
|
mycobacteriosis |
4 |
|
mycosis |
4 |
|
nasopharyngeal neoplasms - complications - therapy |
4 |
|
nasopharynx - virology |
4 |
|
neuraminidase - antagonists & inhibitors - genetics |
4 |
|
novel coronaviruses |
4 |
|
occupational exposure |
4 |
|
oseltamivir - pharmacology |
4 |
|
parengyodontium |
4 |
|
parengyodontium album |
4 |
|
peritoneal dialysis effluent |
4 |
|
pneumococcal infections - complications - diagnosis - pathology - therapy |
4 |
|
poultry |
4 |
|
poultry workers |
4 |
|
progressive outer retinal necrosis |
4 |
|
proteinase k |
4 |
|
psoas abscess - microbiology |
4 |
|
pulmonary delivery |
4 |
|
q fever |
4 |
|
q fever - diagnosis - epidemiology |
4 |
|
re-infection |
4 |
|
reactive dermatosis |
4 |
|
rectum - microbiology |
4 |
|
renal transplantation |
4 |
|
rep-pcr dna fingerprinting |
4 |
|
resistance |
4 |
|
rna binding protein |
4 |
|
rodentia - microbiology |
4 |
|
serological surveillance |
4 |
|
severe acute respiratory syndrome coronavirus (sars-cov) |
4 |
|
severe acute respiratory syndrome coronavirus 2 |
4 |
|
strongyloidiasis |
4 |
|
sweet's syndrome |
4 |
|
tickborne diseases |
4 |
|
vaccination |
4 |
|
yeasts |
4 |
|
zoonoses |
4 |
|
adverse effect |
3 |
|
aedes |
3 |
|
airborne |
3 |
|
albendazole |
3 |
|
amino terminal sequence |
3 |
|
anti-aquaporin-4 antibody |
3 |
|
anti-bacterial agents - therapeutic use |
3 |
|
attitude of health personnel |
3 |
|
avian influenza a h9n2 |
3 |
|
avian influenza h7n9 |
3 |
|
bacterial infections - diagnosis - drug therapy |
3 |
|
bone marrow transplantation |
3 |
|
bone marrow transplantation - adverse effects |
3 |
|
breast milk |
3 |
|
broadly neutralizing antibody |
3 |
|
burkholderia cepacia |
3 |
|
clinical article |
3 |
|
combinational therapy |
3 |
|
community-acquired infections - drug therapy - microbiology |
3 |
|
community-acquired legionellosis |
3 |
|
contact tracing |
3 |
|
coronavirus infection |
3 |
|
delayed viral clearance |
3 |
|
dose optimization |
3 |
|
droplet |
3 |
|
drug utilization - standards |
3 |
|
ebola virus disease |
3 |
|
ebolavirus |
3 |
|
electronics - instrumentation - methods - organization and administration |
3 |
|
enterococcus faecium - growth & development - pathogenicity |
3 |
|
erythema nodosum |
3 |
|
exit-site infection |
3 |
|
gram-positive bacterial infections - epidemiology - prevention & control |
3 |
|
guideline adherence - organization and administration |
3 |
|
guideline adherence - statistics & numerical data |
3 |
|
hand hygiene |
3 |
|
handwashing - standards |
3 |
|
health services research |
3 |
|
hospitals |
3 |
|
human betacoronavirus 2c emc/2012 |
3 |
|
hygiene - standards |
3 |
|
immunocompromised |
3 |
|
immunocompromised host |
3 |
|
infection control - instrumentation - methods - organization and administration - standards |
3 |
|
influenza a virus, h9n2 subtype - classification - genetics - isolation and purification |
3 |
|
influenza, human - complications - diagnosis - pathology - virology |
3 |
|
iterferon gamma |
3 |
|
lymphohistiocytosis, hemophagocytic |
3 |
|
methicillin-resistant staphylococcus aureus |
3 |
|
methicillin-resistant staphylococcus aureus - isolation & purification |
3 |
|
monte carlo method |
3 |
|
mp1p enzyme immunoassay |
3 |
|
mycobacterium |
3 |
|
n-terminal domain |
3 |
|
neuromyelitis optica |
3 |
|
nosocomial legionellosis |
3 |
|
organizational policy |
3 |
|
pancytopenia |
3 |
|
pathology |
3 |
|
penicilliosis |
3 |
|
peritoneal dialysis |
3 |
|
prescriptions - standards |
3 |
|
quaternary epitope |
3 |
|
regression modeling |
3 |
|
respiratory insufficiency - diagnosis - etiology |
3 |
|
severe acute respiratory syndrome |
3 |
|
st414 |
3 |
|
staphylococcal infections - drug therapy - microbiology |
3 |
|
subdomain 1 |
3 |
|
talaromyces marneffei |
3 |
|
talaromycosis |
3 |
|
vancomycin resistance |
3 |
|
vancomycin-resistant enterococcus faecium |
3 |
|
west africa |
3 |
|
chaphamaparvovirus |
2 |
|
chickenpox |
2 |
|
crocodile |
2 |
|
healthcare worker |
2 |
|
iris |
2 |
|
nephrotic syndrome |
2 |
|
novel virus |
2 |
|
parvoviridae |
2 |
|
pattern recognition receptors |
2 |
|
strongyloides stercoralis |
2 |
|
tilapia |
2 |
|
tropheryma whipplei |
2 |
|
weight gain |
2 |
|
whipple’s disease |
2 |
|
aids |
1 |
|
alcohol-based hand rub |
1 |
|
alcohols - pharmacology |
1 |
|
caliciviridae infections - epidemiology - prevention & control |
1 |
|
cross infection - epidemiology - prevention & control |
1 |
|
cryptosporidium |
1 |
|
disease outbreaks - prevention & control |
1 |
|
disinfectants - pharmacology |
1 |
|
gp60 |
1 |
|
hand disinfection - methods |
1 |
|
hiv |
1 |
|
macaca fascicularis |
1 |
|
macaca mulatta |
1 |
|
mixed blood cultures |
1 |
|
mp1p |
1 |
|
mrsa |
1 |
|
multiplex |
1 |
|
norovirus - isolation & purification |
1 |
|
ssu rrna |
1 |
|
standard and transmission based precautions |
1 |
|
vre |
1 |
